Supplemental Financial Statement Information | Supplemental Financial Statement Information Cash Equivalents and Short-Term Investments The following tables summarize the cost or amortized cost, gross unrealized gain, gross unrealized loss and fair value of the Company’s cash equivalents and short-term investments as of the dates indicated (in thousands): December 31, 2023 Cost or Unrealized Estimated Gains Losses Unrestricted Balances (1) Money market funds $ 28,351 $ — $ — $ 28,351 Money market deposit accounts 117,626 — — 117,626 Certificates of deposit 179,607 200 (4) 179,803 Commercial paper 918,278 584 (331) 918,531 Corporate bonds 29,171 6 (5) 29,172 U.S. government securities 231,926 82 — 232,008 Total unrestricted cash equivalents and short-term investments 1,504,959 872 (340) 1,505,491 Restricted Balances (2) Money market funds 44,241 — — 44,241 Term deposits 3,539 — — 3,539 Certificates of deposit 144,935 175 (1) 145,109 Commercial paper 618,854 366 (146) 619,074 Corporate bonds 12,409 3 (1) 12,411 U.S. government securities 224,635 84 — 224,719 Total restricted cash equivalents and investments 1,048,613 628 (148) 1,049,093 Total unrestricted and restricted cash equivalents and investments $ 2,553,572 $ 1,500 $ (488) $ 2,554,584 _______________ (1) Excludes $179.7 million of cash, which is included within the $1.7 billion of cash and cash equivalents and short-term investments on the consolidated balance sheets. (2) Excludes $1.4 million of restricted cash, which is included within the $1.0 billion of restricted cash and cash equivalents and restricted short-term investments on the consolidated balance sheets. December 31, 2022 Cost or Unrealized Estimated Gains Losses Unrestricted Balances (1) Money market funds $ 3,276 $ — $ — $ 3,276 Money market deposit accounts 126,994 — — 126,994 Term deposits 5,000 — — 5,000 Certificates of deposit 502,374 295 (510) 502,159 Commercial paper 964,410 403 (1,663) 963,150 Corporate bonds 61,605 — (104) 61,501 U.S. government securities 7,059 1 — 7,060 Total unrestricted cash equivalents and short-term investments 1,670,718 699 (2,277) 1,669,140 Restricted Balances (2) Money market funds 93,362 — — 93,362 Term deposits 3,539 — — 3,539 Certificates of deposit 355,241 174 (437) 354,978 Commercial paper 596,213 243 (865) 595,591 Corporate bonds 14,933 — (17) 14,916 U.S. government securities 74,699 2 (167) 74,534 Total restricted cash equivalents and investments 1,137,987 419 (1,486) 1,136,920 Total unrestricted and restricted cash equivalents and investments $ 2,808,705 $ 1,118 $ (3,763) $ 2,806,060 _______________ (1) Excludes $126.5 million of cash and $1.1 million in marketable equity securities, which is included within the $1.8 billion of cash and cash equivalents and short-term investments on the consolidated balance sheets. (2) Excludes $1.3 million of restricted cash, which is included within the $1.1 billion of restricted cash and cash equivalents and restricted short-term investments on the consolidated balance sheets. The Company’s short-term investments consist of available-for-sale debt securities and term deposits. The term deposits are at cost, which approximates fair value. The remaining maturity of the Company’s investment portfolio was less than one year as of the periods presented. No individual security incurred continuous unrealized losses for greater than 12 months. The Company purchases investment grade marketable debt securities which are rated by nationally recognized statistical credit rating organizations in accordance with its investment policy. This policy is designed to minimize the Company's exposure to credit losses. As of December 31, 2023, the credit-quality of the Company’s marketable available-for-sale debt securities had remained stable. The unrealized losses recognized on marketable available-for-sale debt securities as of December 31, 2023 were primarily related to the continued market volatility associated with uncertain economic outlook. The contractual terms of these investments do not permit the issuer to settle the securities at a price less than the amortized cost basis of the investments and it is not expected that the investments would be settled at a price less than their amortized cost basis. The Company does not intend to sell the investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost basis. The Company is not aware of any specific event or circumstance that would require the Company to change its quarterly assessment of credit losses for any marketable available-for-sale debt security as of December 31, 2023. These estimates may change, as new events occur and additional information is obtained, and will be recognized on the consolidated financial statements as soon as they become known. No credit losses were recognized as of December 31, 2023 for the Company’s marketable and non-marketable debt securities. The following table summarizes the Company’s available-for-sale debt securities in an unrealized loss position for which no allowance for credit losses was recorded, aggregated by major security type (in thousands): December 31, 2023 Estimated Fair Value Unrealized Losses Certificates of deposit $ 31,945 $ (5) Corporate bonds 14,621 (6) Commercial paper 128,645 (473) Total available-for-sale debt securities in an unrealized loss position $ 175,211 $ (484) Property and Equipment, net Property and equipment, net consisted of the following as of the dates indicated (in thousands): December 31, 2023 2022 Bike and scooter fleet $ 240,137 $ 179,330 Owned vehicles 197,703 143,391 Finance lease right-of-use assets 80,934 32,887 Leasehold improvements 77,230 91,334 Computer equipment and software 38,911 36,271 Furniture and fixtures 5,867 5,602 Construction in progress 72,257 48,523 713,039 537,338 Less: Accumulated depreciation (247,195) (223,936) Property and equipment, net $ 465,844 $ 313,402 Depreciation and amortization expense related to property and equipment was $96.3 million, $127.8 million, and $115.3 million for the years ended December 31, 2023, 2022 and 2021, respectively. Accrued and Other Current Liabilities Accrued and other current liabilities consisted of the following as of the dates indicated (in thousands): December 31, 2023 2022 Insurance-related accruals (1) $ 643,147 $ 566,831 Legal and tax related accruals 296,336 458,209 Ride-related accruals 212,114 181,138 Long-term debt, current 25,798 36,287 Insurance claims payable and related fees 52,609 53,280 Deferred gain related to the Reinsurance Transaction (2) — 2,357 Other 278,851 263,507 Accrued and other current liabilities $ 1,508,855 $ 1,561,609 _______________ (1) Refer to Note 2 “Summary of Significant Accounting Policies” above for more information on these insurance-related accruals. (2) Refer to Note 2 “Summary of Significant Accounting Policies” above and the rest of this Note 6 “Supplemental Financial Statement Information - Insurance Reserves” below for more information on this deferred gain. Insurance Reserves The following table provides a rollforward of the insurance reserve for the periods presented (in thousands): Year Ended December 31, 2023 2022 2021 Balance at beginning of period $ 1,417,350 $ 1,068,628 $ 987,064 Additions (1) 516,337 1,146,482 772,323 Deductions (2) (595,819) (797,760) (690,759) Balance at end of period $ 1,337,868 $ 1,417,350 $ 1,068,628 _______________ (1) Additions to insurance reserves include reserves from claims originating from the current year of $512.3 million, $333.9 million and $271.7 million for the years ended December 31, 2023, 2022 and 2021, respectively. Additions to insurance reserves also include $561.2 million and $255.4 million for the years ended December 31, 2022 and 2021, respectively, for adverse changes in estimates resulting from new developments in claims originating from prior years. Additions also include adjustments related to the Commutation Transaction of $4.0 million and $247.4 million for the years ended December 31, 2023 and 2022, respectively, and $4.0 million and $245.2 million of reinsurance recoverable for the years ended December 31, 2022 and 2021, respectively. See below for more details of the "Commutation of the Reinsurance Agreement". (2) Deductions include losses paid of $580.4 million, $552.6 million and $439.4 million for the years ended December 31, 2023, 2022 and 2021, respectively. Deductions also include $11.4 million for the year ended December 31, 2023 for favorable changes in estimates resulting from new developments in claims originating from prior years and a reinsurance recoverable at the beginning of the period of $4.0 million, $245.2 million and $251.3 million for the years ended December 31, 2023, 2022 and 2021, respectively. Reinsurance of Certain Legacy Auto Liability Insurance On April 22, 2021, the Company’s wholly-owned subsidiary, Pacific Valley Insurance Company, Inc. (“PVIC”), entered into a Quota Share Reinsurance Agreement (the “Reinsurance Agreement”) with DARAG Bermuda LTD (“DARAG”), under which DARAG reinsured a legacy portfolio of auto insurance policies, based on reserves in place as of March 31, 2021, for $183.2 million of coverage above the liabilities recorded as of that date. Under the terms of the Reinsurance Agreement, PVIC ceded to DARAG approximately $251.3 million of certain legacy insurance liabilities for policies underwritten during the period of October 1, 2018 to October 1, 2020, with an aggregate limit of $434.5 million, for a premium of $271.5 million (“the Reinsurance Transaction”). The Reinsurance Agreement was on a funds withheld basis, meaning that funds are withheld by PVIC from the insurance premium owed to DARAG in order to pay future reinsurance claims on DARAG’s behalf. Upon consummation of the Reinsurance Transaction, a reinsurance recoverable of $251.3 million was established, and since a contractual right of offset exists, the reinsurance recoverable was netted against the funds withheld liability balance of $271.5 million for a $20.2 million net funds withheld liability balance included in accrued and other current liabilities on the consolidated balance sheet. In addition to the initial funds withheld balance of $271.5 million, additional coverage of certain legacy insurance liabilities was collateralized by a trust account established by DARAG for the benefit of PVIC, which was $75.0 million upon consummation. At the inception of the Reinsurance Agreement, a loss of approximately $20.4 million for the total cost of the Reinsurance Transaction was recognized on the consolidated statement of operations for the year ended December 31, 2021, with $20.2 million in cost of revenue and $0.2 million in general and administrative expenses. Commutation of the Reinsurance Agreement On June 21, 2022, PVIC and DARAG entered into a Commutation Agreement, which effectively commuted and settled the previous Reinsurance Agreement. Under the terms of the Commutation Agreement, DARAG released $89.3 million of assets held in trust to PVIC and the remaining balance of the funds withheld liability of $90.3 million from the Reinsurance Transaction for a total consideration of $178.6 million. In addition, the Commutation Agreement caused a DARAG affiliate, DNA Insurance Company (“DNA”), to simultaneously enter into an Adverse Development Cover Reinsurance Agreement (“ADC”) with PVIC (the Commutation Agreement and the ADC collectively referred to as the “Commutation Transaction”). Under the terms of the ADC, DNA agreed to reinsure up to $20 million of the legacy insurance liabilities contemplated in the Reinsurance Agreement for a premium of $1.0 million, which would be retained by PVIC on a funds withheld basis. DNA also had the option to commute this agreement for $5.0 million prior to November 1, 2023, which would be offset by any premiums retained as funds withheld. As a result of the Commutation Transaction, the Company noted the following impacts on its financial statements: • The Company recognized a $36.8 million gain in cost of revenue in the three months ended June 30, 2022, including amortization of a portion of the previously recognized deferred gain. • The Company reduced its reinsurance recoverable by $247.4 million and the funds withheld liability balance by $90.3 million. • The Company amortized deferred gains related to losses ceded under the Reinsurance Agreement by $105.7 million. On February 8, 2023, PVIC and DNA entered into a Commutation and Mutual Release Agreement, whereby DNA agreed to exercise its option to fully settle and commute the ADC. DNA commuted the ADC for $5.0 million consisting of a $4.0 million payment made to PVIC and the release of $1.0 million premium which was retained by PVIC as funds withheld. As a result, PVIC recognized a gain of $3.4 million, comprised of $2.4 million amortization of the remaining deferred gain and $1.0 million related to the release of the funds withheld. PVIC also reduced its reinsurance recoverable by $4.0 million related to the payment received. Other Income (Expense), Net The following table sets forth the primary components of other income (expense), net as reported on the consolidated statements of operations (in thousands): Year Ended December 31, 2023 2022 2021 Interest income $ 145,728 $ 47,142 $ 9,074 (Loss) Gain on sale of securities, net (243) (287) 687 Foreign currency exchange gains (losses), net 3,657 (4,387) 788 Sublease income 4,849 11,591 6,624 Gain on equity method investment (1) 12,926 — — Gain from transaction with Woven Planet — — 119,284 Impairment charges (2) — (135,714) — Other, net 3,206 (18,333) (524) Other income (expense), net $ 170,123 $ (99,988) $ 135,933 _______________ (1) In the quarter ended June 30, 2023, the Company received investments in a non-marketable equity security in a privately held company. Refer to Note 17 “Variable Interest Entities” for more information on this transaction. (2) In the third quarter of 2022, the Company impaired the entire amount of a non-marketable equity investment in addition to other assets with the investee. This impairment was triggered due to the announced winding down of the equity investee. Refer to Note 7 “Fair Value Measurements” for additional details. |